Global News

J&J pharma segment poised with over 10 potential new product filings by 2017

Friday, May 24, 2013 01:28 PM

At a meeting with industry analysts, senior leaders from the Janssen Pharmaceutical companies of Johnson & Johnson announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.

More... »

Johannes Schubmehl appointed CIO of Bayer HealthCare

Friday, May 24, 2013 11:31 AM

Bayer HealthCare, a global healthcare company, has appointed Johannes Schubmehl as chief information officer (CIO). Schubmehl succeeds Matthias Moritz, who had left the company at the end of March.

More... »

Corgenix, Eli Lilly ink diagnostic development agreement

Friday, May 24, 2013 10:31 AM

Corgenix Medical, a worldwide developer and marketer of diagnostic test kits, has entered into a collaboration agreement with global pharmaceutical company Eli Lilly to develop diagnostic technology in support of a Lilly oncology pipeline program. The pair will collaborate to further advance this proprietary diagnostic technology originally developed by Lilly.

More... »

Forest Laboratories CEO Howard Soloman to retire

Friday, May 24, 2013 10:02 AM

Forest Laboratories, an international pharmaceutical company, announced that Howard Solomon will retire as chief executive officer and president, effective December 31, 2013. Solomon has served as CEO since 1977, chairman since 1998 and president since 2010.

More... »

Merck announces $5B accelerated share repurchase

Wednesday, May 22, 2013 03:46 PM

Merck, a global healthcare company known as MSD outside the U.S. and Canada, has entered into an accelerated share repurchase agreement (ASR) with Goldman, Sachs & Co. to repurchase $5 billion of Merck's common stock. Proceeds from the company's recently concluded debt offering were used to execute the ASR, which is part of Merck's previously announced $15 billion share repurchase program.

More... »

Grifols, Aradigm sign licensing agreement to develop, commercialize Pulmaquin

Wednesday, May 22, 2013 12:14 PM

Grifols, a global healthcare company, and Aradigm, an emerging specialty pharmaceutical company focused severe respiratory diseases, have signed an exclusive worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed phase IIb clinical trials in BE patients with Pulmaquin and Lipoquin.

More... »

VentureHealth launches new model for funding healthcare innovations

Wednesday, May 22, 2013 11:53 AM

VentureHealth, an online healthcare investment portal for accredited investors, has announced a new model for equity crowdfunding. Focused on innovations that dramatically improve clinical outcomes, VentureHealth is the first equity crowdfunding portal founded by professional investors. The investment platform offers qualified investors access to life sciences deals that traditionally were reserved for venture capitalists.

More... »

UCB, IBM collaborate to personalize care for epilepsy patients

Wednesday, May 22, 2013 11:05 AM

UCB, a Belgium-based global biopharmaceutical company focused on diseases of the immune system and central nervous system, and IBM have completed the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessing the transformative power of cognitive computing capabilities, such as IBM Watson, for epilepsy care.

More... »

Elan announces transactions to transform the company

Wednesday, May 22, 2013 10:42 AM

Elan, a biotechnology company based in Ireland, announced a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement, the dividend pass through, and the completed Tysabri transaction, will form a dynamic and unique business foundation for Elan in the years ahead.

More... »

Nordion, Navidea Biopharmaceuticals ink contract manufacturing agreement

Wednesday, May 22, 2013 10:12 AM

Nordion, a provider of products and services to the global health science market, has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals. Nordion will manufacture [123I] NAV5001 a diagnostic imaging agent used to detect Parkinsonian syndromes and dementia with Lewy bodies.

More... »